<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55467">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076932</url>
  </required_header>
  <id_info>
    <org_study_id>CWS menopause, adipose tissue</org_study_id>
    <nct_id>NCT02076932</nct_id>
  </id_info>
  <brief_title>Effects of Physical Training on Adipose Tissue Metabolism and Insulin Sensitivity in the Menopausal Transition Phase</brief_title>
  <official_title>A Training Intervention Study in Late Pre- and Early Postmenopausal Women Investigating the Changes in Adipose Tissue Metabolism and Peripheral Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if physical exercise reduces the adverse changes
      in adipose tissue metabolism and insulin sensitivity that occurs in women during the
      menopausal transition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Insulin stimulated uptake of glucose in adipose tissue</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by Positron Emission Tomography-Computed tomography (PET/CT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperinsulinemic euglycemic clamp</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glucose metabolized (mg/kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adipose tissue distribution</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accessed by Magnetic Resonance Imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central insulin sensitivity</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting plasma insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen uptake (ml/O2/kg/min)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using indirect calorimetry and an incremental bicycle protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic syndrome</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by high density lipoprotein, triglycerides, waist circumference, blood pressure, mean arterial pressure, fasting glucose and composite metabolic syndrome scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using questionaries, semi-structured interviews and observations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using dual x-ray absorptiometry, height, weight, waist and hip circumference, sagittal abdominal height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle biopsy</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical, proteomics, metabolomics, genomics and morphological analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal subcutaneous adipose tissue biopsy</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical, proteomics, metabolomics, genomics and morphological analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting metabolic rate</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity level and duration of sleep</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daily activity and duration of sleep will be recorded during one week using ActibeltÂ® and self reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microdialysis</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adipose tissue microdialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral subcutaneous adipose tissue biopsy</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical, proteomics, metabolomics, genomics and morphological analyses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dietary registration</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daily food intake for three week days and one week-end day will be reported by the subjects</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Menopause</condition>
  <condition>Insulin Resistance</condition>
  <condition>Body Composition, Beneficial</condition>
  <arm_group>
    <arm_group_label>Premenopausal women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The premenopausal women will be attending Spinning classes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postmenopausal Women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The postmenopausal women will be attending Spinning classes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Spinning</intervention_name>
    <description>After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.</description>
    <arm_group_label>Premenopausal women</arm_group_label>
    <arm_group_label>Postmenopausal Women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal OR Postmenopausal (45-57 years)

          -  No chronical Diseases

          -  BMI &gt; 18,5 and &lt; 30

          -  Sedentary (no regular physical activity the last 2 years)

          -  Either regular bleeding (premenopausal) OR no menstruation for at least 2 years
             (postmenopausal)

          -  Plasma measurements:

        Premenopausal: estradiol &gt; 0.20nmol/l, Follicle Stimulating Hormone &lt; 22 IU/l and
        progesterone &gt; 2.5 nmol/l Postmenopausal: estradiol &lt; 0.20nmol/l, Follicle Stimulating
        Hormone &gt; 22 IU/l and progesterone from 0.3-2.5 nmol/l

        Exclusion Criteria:

          -  Smoking

          -  Excessive alcohol intake

          -  Regular medication including hormone replacement treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>57 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ylva Hellsten, Proff.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bente M Stallknecht, Proff. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla M. Mandrup, MD, PhDstudent</last_name>
    <phone>0045 51906613</phone>
    <email>camillam@sund.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bente M. Stallknecht, Prof., MD</last_name>
    <phone>0045 28757540</phone>
    <email>bstall@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department og Biomedical Sciences</name>
      <address>
        <city>Copenhagen N</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla M Mandrup, MD, PhD-student</last_name>
      <phone>0045 51906613</phone>
      <email>camillam@sund.ku.dk</email>
    </contact>
    <investigator>
      <last_name>Camilla Mandrup, MD, PhD stud</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bente Stallknecht, Proff., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>February 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Bente Merete Stallknecht</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
